Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bionomics Ltd ADR

BNOX
Current price
0.63 USD -0.012 USD (-1.87%)
Last closed 0.66 USD
ISIN US09063M2052
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 8 726 062 USD
Yield for 12 month -40.00 %
1Y
3Y
5Y
10Y
15Y
BNOX
21.11.2021 - 28.11.2021

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. Address: 200 Greenhill Road, Eastwood, SA, Australia, 5063

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6 USD

P/E ratio

Dividend Yield

Current Year

+291 641 USD

Last Year

+2 818 021 USD

Current Quarter

+66 688 USD

Last Quarter

+232 027 USD

Current Year

-8 513 758 USD

Last Year

-4 627 580 USD

Current Quarter

-3 484 485 USD

Last Quarter

-3 742 589 USD

Key Figures BNOX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -25 724 844 USD
Operating Margin TTM -9466.24 %
PE Ratio
Return On Assets TTM -35.13 %
PEG Ratio
Return On Equity TTM -80.8 %
Wall Street Target Price 6 USD
Revenue TTM 661 980 USD
Book Value 2.72 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 9.3 %
Dividend Yield
Gross Profit TTM -18 963 665 USD
Earnings per share -2.04 USD
Diluted Eps TTM -2.04 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BNOX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BNOX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BNOX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 62.941
Price Sales TTM 13.1818
Enterprise Value EBITDA -0.0591
Price Book MRQ 0.4504

Financials BNOX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BNOX

For 52 weeks

0.5 USD 5.3 USD
50 Day MA 0.67 USD
Shares Short Prior Month 333 372
200 Day MA 0.95 USD
Short Ratio 0.08
Shares Short 107 070
Short Percent 0.99 %